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OBJECTIVES The purpose of our study was to characterize the penetrance of PKP2 mutations among family
members of people with arrhythmogenic right ventricular dysplasia/cardiomyopathy
(ARVD/C) and to examine clinical features and predictors of disease among PKP2 mutation
carriers.
BACKGROUND Arrhythmogenic right ventricular dysplasia/cardiomyopathy is an inherited cardiomyopathy
characterized by fatty-fibrous myocardial replacement of the right ventricle, ventricular
arrhythmias, and right ventricular dysfunction. Mutations in PKP2, the gene encoding
plakophilin-2, are found in 11% to 43% of ARVD/C probands.
METHODS The study population was composed of 64 individuals in 9 families with an ARVD/C
proband previously shown to carry a pathogenic PKP2 mutation. The diagnosis of ARVD/C
was established based on task force criteria (TFC) set by the European Society of Cardiology.
RESULTS In addition to the probands, PKP2 mutations were present in 52% of relatives screened.
Forty-nine percent of PKP2 mutation carriers met TFC. Among mutation carriers who did
not meet full TFC, 50% met at least some TFC criteria besides family history. Pedigrees
showed wide intra-familial variability, ranging from severe disease with early death to
individuals who were completely asymptomatic late in life. Male PKP2 mutation carriers were
more likely to have structural and conduction abnormalities as determined by imaging studies,
signal-averaged electrocardiography, and 24-h ambulatory electrocardiography (p  0.05).
CONCLUSIONS PKP2 mutations in a group of North American families with ARVD/C have both reduced
penetrance and variable expressivity. Gender may have an influence on penetrance of PKP2
mutations, with male mutation carriers more likely to develop specific phenotypic manifes-
tations of this disease. (J Am Coll Cardiol 2006;48:1416–24) © 2006 by the American
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.06.045College of Cardiology Foundation
n
v
w
r
i
A
p
A
f
e
A
w
p
m
A
t
g
g
p
drrhythmogenic right ventricular (RV) dysplasia/
ardiomyopathy (ARVD/C) is an inherited cardiomyop-
thy characterized histologically by fibro-fatty myocardial
eplacement of the RV and clinically by ventricular
rrhythmias and RV dysfunction (1,2). Patients with
RVD/C typically present in their mid-teens to mid-
orties with symptomatic ventricular tachycardia (VT) of
left bundle branch block morphology (3). Sudden
ardiac death may be the first manifestation of the disease
3–5). Clinical diagnosis is based on diagnostic criteria
roposed by the International Task Force of the Euro-
ean Society of Cardiology and International Society and
ederation of Cardiology that take into account arrhyth-
ic, electrocardiographic, structural, and histopathologic
bnormalities, as well as family history (6).
From the *Division of Cardiology, Department of Medicine, Johns Hopkins
niversity School of Medicine, Baltimore, Maryland; †Division of Cardiology,
epartment of Pediatrics, Johns Hopkins University School of Medicine, Baltimore,
aryland; and the ‡Department of Radiology, Johns Hopkins University School of
edicine, Baltimore, Maryland. Funding for this work was provided by the D.W.
eynolds Foundation, the Johns Hopkins ARVD Program, and the W.W. Smith
haritable Trust. Drs. Dalal and James contributed equally to this manuscript.e
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ccepted June 6, 2006.Arrhythmogenic RV dysplasia/cardiomyopathy is a ge-
etic disorder transmitted with reduced penetrance and
ariable expressivity. To date, 6 genes have been identified
ith mutations causing ARVD/C. Both dominant and
ecessive forms of ARVD/C are associated with mutations
n DSP, encoding a desmosomal protein, desmoplakin (7,8).
typical forms of ARVD/C are caused by mutations in
lakoglobin (9) and the cardiac ryanodine receptor (10).
ltered expression of TGF-beta-3 has been identified in 2
amilies with dominant ARVD/C (11). Mutations in PKP2,
ncoding plakophilin-2, result in a dominant form of
RVD/C (12). The role of mutations in PKP2 has been
ell established in three different cohorts of ARVD/C
robands across the world (12–14). The proportion of PKP2
utations among apparently unrelated individuals with
RVD/C ranges between 11% and 43%. On the basis of
he hypothesis that ARVD/C is caused by mutations in
enes encoding components of the cardiac desmosome, 2
roups have recently identified mutations in ARVD/C
atients in a fourth desmosome gene, DSG2, encoding
esmoglein-2 (15,16).
One family-based investigation has reported the pen-trance of the disease among PKP2 mutation carriers to be
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October 3, 2006:1416–24 PKP2 Penetrance in ARVD/C7%, although the influence of age and gender on clinical
xpression was not reported (14). The purpose of our study
s to further characterize the penetrance and clinical features
f PKP2 mutations in a North American cohort of families,
nd to examine the influence of age and gender on the
linical manifestation of the disease among family members
f ARVD/C patients with PKP2 mutations.
ETHODS
tudy population. The study population was composed of
4 individuals in 9 ARVD/C families previously shown to
arry a pathogenic PKP2 mutation (13). The proband in
ach family met criteria set by the Task Force of the
orking Group of Myocardial and Pericardial Disease of
he European Society of Cardiology (6). Through an iter-
tive process, clinical evaluation and/or review of medical
ecords and mutation screening was performed on all
vailable first-degree relatives of individuals carrying a PKP2
utation. All subjects gave written informed consent to
articipate in this study, which was approved by a Johns
opkins School of Medicine Institutional Review Board.
atient evaluation and clinical testing. Subjects were
nterviewed to determine family structure and family history
f ARVD/C. The medical history of each subject was
btained by review of medical records, clinical evaluation,
nd patient interview. Pedigrees for each family were
onstructed on the basis of this information.
The clinical protocol for screening relatives included 12-lead
lectrocardiogram (ECG), signal-averaged electrocardiogram
SAECG), 24-h Holter monitoring, 2-dimensional echo-
ardiography, exercise tolerance testing, and cardiac mag-
etic resonance imaging. Cardiac biopsy was recommended
or relatives whose non-invasive testing was suggestive but
ot diagnostic of ARVD/C. Information regarding symp-
oms, sustained VT, diagnosis of ARVD/C, sudden cardiac
eath, and other causes of death was recorded by age.
The results of noninvasive testing were obtained in those
iagnosed while living and in family members. QRS dura-
ion and the duration of the S-wave upstroke on a 12-lead
CG were measured with the image analysis software
igmaScan Pro (Version 5.0) (17). The presence of epsilon
aves and the distribution of T-wave inversions on the
CG were also determined (17). Signal-averaged ECGs
Abbreviations and Acronyms
ARVD/C  arrhythmogenic right ventricular dysplasia/
cardiomyopathy
DNA  deoxyribonucleic acid
ECG  electrocardiogram
ICD  implantable cardioverter-defibrillator
RV  right ventricle/ventricular
SAECG  signal-averaged electrocardiogram
TFC  task force criteria (for diagnosis of ARVD/C)
VT  ventricular tachycardiasing time-domain analysis with a bandpass filter of 40 Hz pere evaluated in subjects who did not have a pre-existing
omplete or incomplete right bundle branch block pattern.
he SAECG was considered positive for late potentials if
ny 2 of the following were present: filtered QRS duration
114 ms, low-amplitude signal duration 38 ms, or RMS
20 V (18). The results of Holter monitoring, baseline
CG, and exercise stress test were used to determine the
resence of sustained or non-sustained VT as well as the
orphology of ventricular ectopy and/or VT. The severity
nd extent of RV dysfunction was determined by imaging
tudies.
iagnosis of ARVD/C. The diagnosis of ARVD/C was
stablished based on the criteria set by the Task Force of the
orking Group of Myocardial and Pericardial Disease of
he European Society of Cardiology and of the Scientific
ouncil on Cardiomyopathies of the International Society
nd Federation of Cardiology (6) , as listed in Table 1. The
iagnosis is established by the presence of 2 major criteria,
major criterion plus 2 minor criteria; or 4 minor criteria.
he patients were classified as having ARVD/C when they
et the full criteria. Family members who satisfied an
ncomplete set of criteria were noted, but not considered to
ave been diagnosed with ARVD/C. Autopsy diagnosis was
stablished in subjects whose first clinical presentation was
eath. Those with the recommended gross as well as
istopathologic evidence of ARVD/C were considered to be
iagnostic of ARVD/C (5).
utation screening. PKP2 mutation identification of in-
ex cases in each pedigree has been described (13). For each
vailable family member, genomic deoxyribonucleic acid
DNA) was extracted from leukocytes present in whole
lood using QIAmp DNA blood maxi kits (Qiagen, Inc.,
alencia, California). Intronic PKP2 primers flanking each
xon were used as previously described (12). For mutations
hat result in gain or loss of a restriction enzyme digest site,
ll family members were compared with the mutation
arrier for presence or absence of the mutant allele by
estriction enzyme digest of polymerase chain reaction
mplicons using intronic primers flanking the exon with the
utation. All other mutations were assessed by bidirectional
equence analysis using an ABI 3730 DNA Analyzer
Applied Biosystems, Foster City, California) and chro-
atograms were analyzed with Sequencher 4.1 software.
tatistical analysis. Qualitative data obtained as recom-
ended by the task force criteria (TFC), were expressed as
requency (%). Continuous variables were expressed as mean
D. A two-tailed chi-square or Fisher exact test was used
or categorical variables and a two-tailed t test was used for
ontinuous variables to test the null hypothesis of no
ifference between subgroups of patients.
Kaplan-Meier analysis was used to examine the freedom
rom the following events since birth (i.e., by age): 1) any
ymptom consistent with ARVD/C, 2) meeting TFC for
RVD/C, 3) symptomatic VT, and 4) death. This analysis
as performed on individuals from all pedigrees and re-
eated after exclusion of the probands. All statistical anal-
y
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PKP2 Penetrance in ARVD/C October 3, 2006:1416–24ses were performed using the STATA statistical software
version 8.2, STATA Corp., College Station, Texas). A p
alue of 0.05 was considered statistically significant.
ESULTS
revalence of ARVD/C in PKP2 mutation carriers. Eight
ifferent PKP2 mutations (1 recurrent) were present in the
unrelated families screened. Family pedigrees indicating
utation status and significant cardiac events in subjects are
hown in Figure 1. In addition to the 9 probands, PKP2
utations were present in 27 of the 52 genetically screened
elatives (52%). Families A, E, and I each included 1
bligate mutation carrier. The obligate carrier in family A
A:I:2) was the brother of a PKP2 mutation carrier and
ather of 4 PKP2 mutation carriers; his spouse did not carry
he PKP2 mutation. He experienced sudden cardiac death
uring exercise at age 36. Families E and I included
eceased identical twins who were obligate carriers (E:III:1
nd I:II:3). In total, 39 of the 64 ascertained individuals
61%) were determined to have a PKP2 mutation. Nucleo-
ide and amino acid changes associated with these muta-
ions are presented in Table 2.
Clinical and genetic data on each of the 39 PKP2
utation carriers are presented in detail in Table 2. Four
amily members (A:II:1, A:I:1, B:II:2, I:II:1) declined to
able 1. Task Force Criteria for the Diagnosis of ARVD/C
. Global and/or regional dysfunction and structural alterations*
MAJOR
— Severe dilation and reduction of right ventricular ejection fraction
— Localized right ventricular aneurysms (akinetic or dyskinetic areas
— Severe segmental dilatation of the right ventricle
MINOR
— Mild global right ventricular dilatation and/or ejection fraction re
— Mild segmental dilatation of the right ventricle
— Regional right ventricular hypokinesis
I. Repolarization abnormalities
MINOR
— Inverted T-waves in the right precordial leads (V2 and V3) of a 1
in absence of right bundle branch block)
II. Depolarization/conduction abnormalities
MAJOR
— Epsilon waves or localized prolongation (110 ms) of the QRS c
MINOR
— Late potentials on a signal averaged electrocardiogram
V. Arrhythmias
MINOR
— Left bundle branch block type ventricular tachycardia (sustained o
— Frequent ventricular extrasystoles (more than 1,000/24 h) on a H
. Tissue characterization of walls
MAJOR
— Fibrofatty replacement of myocardium on endomyocardial biopsy
I. Family history
MAJOR
— Familial disease confirmed at necropsy or surgery
MINOR
— Familial history of premature sudden death (35 yrs) due to susp
— Familial history (clinical diagnosis in a family member based on p
Detected by echocardiography, angiography, magnetic resonance imaging, or radion
ARVD/C  arrhythmogenic right ventricular dysplasia/cardiomyopathy; ECG ndergo comprehensive clinical screening. Of the remaining t5 PKP2 mutation carriers, 17 (49%) were diagnosed with
RVD/C on the basis of either the TFC or gross and
istopathologic evidence on autopsy. With exclusion of
robands, 8 of the 26 mutation carriers (31%) were diag-
osed with ARVD/C. The obligate carrier in family A
A:I:2) died suddenly at age 36, but his autopsy, performed
lmost 40 years ago, was inconclusive for ARVD/C.
linical features of PKP2mutation carriers. As shown in
able 2, 19 of the 39 PKP2 mutation carriers (49%)
xperienced symptoms associated with ARVD/C. The most
ommon symptoms included palpitations, presyncope, and
yncope. Among the 17 patients diagnosed with ARVD/C,
3 (76%) had symptoms related to ARVD/C. These in-
luded 8 of the 9 probands (89%) and 5 of the 8 family
embers (63%). Among the remaining 22 PKP2 mutation
arriers, 6 experienced symptoms (27%), including palpita-
ions (n  4), syncope and palpitations (n  1), and sudden
eath (n  1).
Among those 18 PKP2 mutation carriers with compre-
ensive screening who were not diagnosed with ARVD/C,
(50%) had evidence of incomplete penetrance or variable
xpressivity of the PKP2 mutation by meeting at least some
FC other than family history. Three individuals met a single
inor criterion, 4 met two minor criteria, and 2 PKP2
utation carriers met one major criterion for ARVD/C other
no (or only mild) left ventricular impairment
diastolic bulging)
n with normal left ventricle
electrocardiogram (in individuals aged more than 12 years of age;
ex in right precordial leads (V1–V3) of a 12-lead electrocardiogram
-sustained) on ECG, Holter, or exercise tolerance testing
monitor
right ventricular dysplasia/cardiomyopathy
t criteria)
scintigraphy.
rocardiogram.with
with
ductio
2-lead
ompl
r non
olter
ected
resenhan criteria for family history. Among the 9 PKP2 muta-
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October 3, 2006:1416–24 PKP2 Penetrance in ARVD/Cion carriers that did not meet any criteria for ARVD/C
ther than family history, 4 of these individuals were age 20
ears or younger.
Among the 39 PKP2 mutation carriers, 35 were living at
ost recent follow-up. Four had died from ARVD/C (3 of
udden cardiac death, 1 of biventricular heart failure). Two
ubjects had received a heart transplant, 1 (C:I:1) at age of
7 because of incessant VT and the other (F:II:1) at age 33
rom heart failure and incessant VT. Except for 1 case of
udden death, each of these outcomes occurred in a family’s
roband.
enetrance of PKP2 mutations is age-dependent. Figure 2
resents Kaplan-Meier curves documenting the age depen-
ence of the clinical course of PKP2 mutation carriers.
igure 2A shows freedom from: 1) symptoms, 2) diagnosis
igure 1. Pedigrees of families with a PKP2 mutation. Circles and squares
he phenotypes of individuals: white  unaffected; black  affected; blue
nformation available.  indicates the presence of a PKP2 mutation and 
lanting bar indicates a deceased individual.meeting TFC), 3) ventricular tachycardia, and 4) death in All PKP2 mutation carriers. The line indicating diagnosis by
FC excludes subjects with incomplete clinical testing.
igure 2B excludes all probands.
For probands and family members, development of
ymptoms, diagnosis, symptomatic VT, and death all appear
o be age-dependent phenomena with incomplete pen-
trance even at an advanced age.
nfluence of gender on penetrance of PKP2 mutations.
lthough 10 of 15 (67%) of male PKP2 mutation carriers
ho were comprehensively evaluated were diagnosed with
RVD/C, only 7 of 20 (35%) of female mutation carriers
et TFC (p  0.06). This trend of gender dependence
ordering on statistical significance led us to investigate
ifferent measures of severity of the disease between the 2
enders. Table 3 shows the results of cardiac testing for
ate women and men, respectively. Filling in the circles/squares indicates
lfill an incomplete set of task force criteria; and red  inadequate clinical
ates the absence thereof. Arrowhead indicates the proband of the family.indic
 fu
indicRVD/C among male and female PKP2 mutation carriers
Table 2. Clinical and Genetic Characteristics of Subjects With PKP2 Mutations
Case
Nucleotide
Change
Amino-Acid
Change Gender
Presenting
Symptom Age
Fam
FH
Depol
Repol
TWI
Arrhyth Struct
HPEW QRS LP DSW LBBB PVC G.Dil Aneu WMA
A, I, 1 1642delG V548fsX562 M Asymptomatic 70 HP  None  
A, I, 2 1642delG V548fsX562 M SCD 36 
A, II, 1 1642delG V548fsX562 M Asymptomatic 44 HP  None  
A, II, 2 1642delG V548fsX562 F Palpitations 50 HP     V1  None  
A, II, 5 1642delG V548fsX562 F Syncope 36 SCD    V1–V4   Mod   
A, II, 7 1642delG V548fsX562 M Palpitations 37 HP     V1–V3   Mild  
A, III, 1 1642delG V548fsX562 M Asymptomatic 20 HP  V1  None  
A, III, 2 1642delG V548fsX562 F Palpitations 17 HP     V1  None  
A, III, 3 1642delG V548fsX562 F Asymptomatic 16 HP     V1   None  
A, III, 4 1642delG V548fsX562 F Asymptomatic 13 HP     V1–V2   None  
B, II, 2 2011delC P671fsX683 F Asymptomatic 83 TFC
B, III, 2 2011delC P671fsX683 F Asymptomatic 54 TFC     — 
B, III, 3 2011delC P671fsX683 F Syncope, palpitations 53 TFC    V1–V4  None  
B, III, 5 2011delC P671fsX683 M Asymptomatic 43 TFC     —  None  
B, III, 7 2011delC P671fsX683 M Palpitations 51 TFC     V1   Mild  
B, IV, 1 2011delC P671fsX683 F Palpitations, nausea 21      V1–V4   Mild   
B, IV, 2 2011delC P671fsX683 M Asymptomatic 23 TFC     V1–V4   Mild   
C, I, 1 145-148delCAGA S50fsX110 M Palpitations, near
syncope, nausea
67      V2–V4   Sev   
C, II, 3 145-148delCAGA S50fsX110 F Near syncope 42 HP     V1–V3   Mild  
C, II, 4 145-148delCAGA S50fsX110 F Asymptomatic 37 HP     V1–V2   None  
D, I, 2 2509delA V837fsX740 F Asymptomatic 48 TFC  V1–V3  None  
D, II, 1 2509delA V837fsX740 M Palpitations, VT 25      V1–V6   Mod   
D, II, 2 2509delA V837fsX740 F Palpitations 21 TFC     V1–V3   Mild   
D, II, 4 2509delA V837fsX740 M Asymptomatic 15 TFC     V1–V4   Mild   
E, II, 2 2146-1G¡C abn splice product F Asymptomatic 56 HP  V1–V2   None  
E, III, 1 2146-1G¡C abn splice product M Presyncope 19  Mod 
E, III, 2 2146-1G¡C abn splice product M Presyncope 28 HP     V1–V4   Mild  
F, I, 2 2146-1G¡C abn splice product F Asymptomatic 62 HP     —   None  
F, II, 1 2146-1G¡C abn splice product M VT 33      V1–V5   Sev   
F, II, 2 2146-1G¡C abn splice product F Palpitations 36 HP     V1–V2   None  
G, II, 1 1613G¡A W538X F Asymptomatic 31 TFC     V1–V3   Mild   
G, II, 3 1613G¡A W538X M VT 29      V1–V5   Mod   
H, I, 1 24891G¡A abn splice product M Asymptomatic 55 HP     V1   None  
H, II, 3 24891G¡A abn splice product M Asymptomatic 18 HP     V1–V3   Mild  
I, I, 2 1271T¡C F424S F Asymptomatic 60 TFC     —   None  
I, II, 1 1271T¡C F424S M Asymptomatic 37 TFC 
I, II, 2 1271T¡C F424S F Asymptomatic 34 TFC    V1–V3   None  
I, II, 3 1271T¡C F424S F VT 27      V1–V5   Sev  
I, II, 4 1271T¡C F424S F Palpitations 33 TFC     V1–V4   None   
Aneu  localized aneurysms (akinetic or dyskinetic areas with diastolic bulging); Arrhyth  arrhythmias; Depol  depolarization abnormalities; DSW  delayed S-wave upstroke; EW  presence of epsilon wave in precordial leads on a 12-lead
electrocardiogram; F female; Fam family history suggestive of ARVD/C; FH family history; G. dil. global right ventricular dilation with no left ventricular impairment; HP indicates diagnosis of a family member with ARVD/C based
on histopathologic evidence; HP  histopathologic abnormalities; LBBB  left bundle branch block-type ventricular tachycardia on electrocardiogram, exercise tolerance test or 24-h Holter monitor; LP  late potentials on signal-averaged
electrocardiogram; M  male; PVC  more than 1,000 premature ventricular contractions on a 24-h Holter monitor; QRS  localized QRS prolongation in precordial leads on a 12-lead electrocardiogram; Repol  repolarization abnormalities;
SCD  sudden cardiac death; SCD (under FH)  indicates sudden cardiac death in a family member at an age 35; Struc  right ventricular structural abnormalities; TFC  indicates diagnosis of ARVD/C in a family member based on
International Task Force criteria; TWI  T-wave inversions in leads V1 through V3 and beyond on a 12-lead electrocardiogram; WMA  wall motion abnormalities of right ventricle (regional hypokinesia);   indicates presence of a certain
characteristic;   indicates absence of a certain characteristic.
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October 3, 2006:1416–24 PKP2 Penetrance in ARVD/Cummarizing the frequency of each of the TFC. Men were
ignificantly more likely (p  0.05) to have late potentials
n a SAECG, frequent ventricular extrasystoles on a 24-h
olter monitor, and evidence of RV dilation on imaging
tudies (p 0.05). There was no significant difference in the
ge of diagnosis of ARVD/C between men (mean 29  14
ears) and women (mean 31  11 years). There was no
ignificant difference in age of surviving male and female
KP2 mutation carriers at most recent follow-up.
linical discordance in identical twins. The pedigrees
ncluded 2 sets of monozygotic twins (E:III:1 E:III:2 and
:II:3  I:II:4) with PKP2 mutations who were concordant
or ARVD/C but discordant for disease severity. In family
, one twin died suddenly during exercise at age 19 with
RVD/C diagnosed on autopsy. He had experienced sev-
ral presyncopal episodes before his death. His brother was
creened at that time and found to meet criteria for
RVD/C, and an implantable cardioverter-defibrillator
ICD) was implanted for primary prevention shortly there-
fter. The surviving brother, now age 28, continued to do
ell. His ICD never discharged to treat VT. He had no
ymptoms of heart failure, and he had only mild RV dilation
nd mild RV wall motion abnormalities. The twins’ mother
igure 2. Kaplan-Meier curves demonstrating the proportion of individ-
als free from: 1) symptoms, 2) diagnosis, 3) symptomatic ventricular
rrhythmia, and 4) cardiac death among (A) all PKP2 mutation carriers and
B) all family members with a PKP2 mutation after exclusion of the
robands. VT  ventricular tachycardia.lso had a PKP2 mutation; she had an incomplete right tundle branch block pattern on ECG but showed no signs
f ARVD/C at age 56.
In family I, the proband initially presented with VT
uring exercise at age 15. She was eventually diagnosed with
RVD/C in her early ‘20s and died of biventricular heart
ailure at age 27. Her twin sister was diagnosed with
RVD/C after being screened at age 28. An ICD was
mplanted at age 31 after a loop recorder showed several
pisodes of non-sustained VT. She was doing well at age 33
ith one episode of ICD firing for sustained VT, no
vidence of heart failure symptoms, and only mild RV
ilation.
ISCUSSION
ur results show that PKP2 mutations in a group of North
merican families with ARVD/C have both reduced pen-
trance and variable expressivity. Despite increasing inci-
ence of clinical disease with increased age, some mutation
arriers remain without evidence of ARVD/C throughout
heir lifetime. Despite a similar age at onset of clinical
isease, male PKP2 mutation carriers are more likely to have
ate potentials on a SAECG, frequent ventricular extrasys-
oles on a 24-h Holter monitor, and RV dilation on imaging
tudies.
mportance of understanding penetrance in a genetic dis-
ase. Currently, we and others recommend that all first-
egree relatives of a proband with ARVD/C undergo
omprehensive screening every 1 to 3 years. As sudden
ardiac death may be the initial symptom, early use of ICDs
n those at highest risk of life-threatening cardiac arrhyth-
ia seems warranted. However, ICD placement is not
ithout risk, including procedural complications, inappro-
riate shocks, and psychological burden.
As genetic testing for heritable cardiovascular diseases
roceeds to clinical use, understanding the implications of a
ositive genetic test is critical. By itself, inheritance of a
KP2 mutation that was previously identified in a proband
hould lead to closer clinical screening for that family
ember. Asymptomatic PKP2 mutation carriers may be
eassured by the relatively low penetrance associated with
uch mutations and not automatically assumed to be des-
ined to the clinical course of the proband in that family.
nfluence of age and gender. Arrhythmogenic RV dysplasia/
ardiomyopathy is an age-dependent disorder, with a me-
ian age at presentation in the U.S. of 26 years and a range
f onset in symptoms between 2 and 70 years (3). Thus,
stimates of penetrance must be tied to the age of the
opulation studied, acknowledging that younger individuals
ithout phenotypic features may later develop this condi-
ion. Accurate analysis of penetrance on the basis of age also
llows proper counseling for mutation carriers at young ages
o estimate their lifetime risk. Our pedigrees include indi-
iduals age 70 years or greater who remain free of all discern-
ble manifestations of ARVD/C (A:I:1, B:II:2), suggesting
rue non-penetrance of PKP2 mutations. Additionally, there
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PKP2 Penetrance in ARVD/C October 3, 2006:1416–24re several individuals age 50 years or greater who show few if
ny signs of ARVD/C (that is, A:II:2, F:I:2, E:II:2).
The influence of male gender on some phenotypic manifes-
ations of ARVD/C achieves statistical significance in our
opulation, suggesting that men may be at greater risk of this
ondition. Two reports describing the clinical characteristics of
amily members of ungenotyped ARVD/C cases show a male
reponderance of cases. In a study of 37 Italian families with
RVD/C, 62% of individuals with ARVD/C were men (19).
imilarly, Hamid et al. (20) found that among first-and
econd-degree relatives of ARVD/C cases in Western Europe,
0% met TFC for ARVD/C, 72% of them men.
Lower penetrance among women may be the result of
esser exposure to environmental factors hypothesized to
rigger ARVD/C in susceptible individuals, such as sus-
ained vigorous athletic activity or exposure to viral agents
ausing inflammation. Alternately, the reduced penetrance
ay result from biological differences. For instance, it is
hought that myocyte apoptosis plays a role in the patho-
enesis of ARVD/C because apoptotic myocytes have been
ound in endomyocardial biopsies and autopsy tissue from
RVD/C patients (21,22). The inhibitory effect of estro-
ens on myocardial cell apoptosis has previously been
able 3. Patient Characteristics in PKP2 Mutation Carriers
Clinical Characteristics
resenting symptoms
Palpitations
Syncope
Near syncope
Asymptomatic
eath
Sudden
Heart failure
lobal and/or regional dysfunction and structural abnormalities
Dilation and reduction of right ventricular EF with no LV impairment
Moderate to severe*
Mild†
Localized ventricular aneurysms*
Regional right ventricular hypokinesis†
epolarization abnormalities
Prolongation of QRS in leads V1–V3*
Presence of epsilon waves†
Late potentials on SAECGa†
S-wave upstroke 55 ms in leads V1–V3
epolarization abnormalities
Inverted T-waves in leads V1 through V3 or beyond†
rrhythmias
Left bundle branch block-type VT documented†
Frequent ventricular extrasystolesa†
amily history
Family history confirmed by biopsy or autopsy*
Sudden cardiac death in family at 35 yrs of age†
Family members diagnosed by using the present criteria†
issue characterization of walls
Infiltration of RV by fat with presence of surviving strands or cardiomy
Major criteria; †minor criteria. aPresence of dilation of the right ventricle (RV
lectrocardiogram (SAECG) were significantly different between men and women (p
EF  ejection fraction; LV  left ventricle; SAECG  signal averaged electroceported (23). hnfluence of environmental factors. Our presentation of 2
ets of identical twins with ARVD/C and discordant sever-
ty of disease strongly implicates environmental factors in
he pathogenesis of this condition. Identical twins not only
hare the same PKP2 mutation, but also any other possible
enetic modifiers of this condition. Thus, factors such as
xposure to viruses and aerobic activity may be responsible
or differences in rates of ventricular arrhythmia and severity
f structural RV dysfunction.
The mechanism by which male gender results in greater
isk of some manifestations of ARVD/C is not known. At
hysiologic concentration, 17-beta-estradiol prevents pro-
rammed cell death in myocardial cells (24). This may be
rotective in ARVD/C, where increased apoptosis of ven-
ricular myocytes has been invoked in the pathogenesis (21).
lthough protective hormonal or genetic factors that are
ender-linked may be the primary reason, men may also be
t higher risk of environmental factors that appear to
nfluence disease outcomes.
amily history in the diagnosis of ARVD/C. Currently,
he influence of family history in establishing a diagnosis of
RVD/C is variable, with some cases resulting in a major
riterion and others a minor criterion. If a family member
Men
(n  18)
Women
(n  21)
Total
(n  39)
4 (22) 7 (33) 11 (28)
0 (0) 2 (10) 2 (5)
1 (6) 1 (5) 2 (5)
9 (50) 11 (52) 20 (51)
2 (11) 1 (5) 3 (8)
0 (0) 1 (5) 1 (3)
5/16 (31) 2/19 (11) 7/35 (20)
6/16 (38) 4/19 (21) 10/35 (29)
1/15 (7) 1/19 (5) 2/34 (6)
8/15 (53) 5/19 (26) 13/24 (38)
6/12 (50) 4/19 (21) 10/31 (32)
3/12 (25) 1/19 (5) 4/31 (13)
9/13 (69) 5/18 (28) 14/31 (45)
8/12 (67) 11/18 (61) 19/30 (63)
9/13 (69) 10/21 (48) 19/34 (56)
6/16 (38) 5/20 (25) 11/36 (31)
8/11 (73) 5/15 (33) 13/26 (50)
7 (39) 9 (43) 16 (41)
1 (0.5) 0 (0) 1 (0.3)
4 (22) 10 (48) 14 (36)
s* 3/7 (43) 1/5 (20) 4/12 (33)
000 PVCs on a 24-h Holter monitor, and late potentials on a signal-averaged
05).
am; PVC  premature ventricular complex; VT  ventricular tachycardia.a
ocyte
), 1,as ARVD/C confirmed at autopsy or surgery (such as
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October 3, 2006:1416–24 PKP2 Penetrance in ARVD/Cardiac transplantation), all first-degree relatives meet a
ajor criterion for ARVD/C. In contrast, if ARVD/C is
linically and independently diagnosed in a proband, then
ll first-degree relatives achieve a minor criterion for this
ondition. Sudden death at age 35 years from suspected
RVD/C also provides family members with a minor
riterion. Biopsy, an invasive procedure, is difficult to obtain
n all subjects being evaluated for ARVD/C. Moreover,
ven among those who undergo it, the results lack sensitivity
or demonstrating fibrofatty replacement (3,25). As a result,
ome family members may not receive a major criterion (and
ometimes a diagnosis) on the basis of the current recom-
endations of the task force, in spite of the proband having
n overt clinical disorder. If the presence of a PKP2
utation is included as a major criterion under family
istory, the diagnosis of ARVD/C would be made in 50% of
amily members who carry this mutation. In contrast, under
he current criteria, only 30% of mutation carrier family
embers currently satisfy TFC. As the clinical conse-
uences of mutations in ARVD/C-associated genes become
etter recognized, the current TFC should be reviewed to
valuate the possibility of substituting genetic mutations for
amily history as either a minor or major criterion.
tudy limitations. Complete cardiac evaluation was not
erformed in all first-degree relatives in all families, either
ecause some family members were unwilling or unable to
ndergo comprehensive testing or declined inclusion of such
esting in our analysis. This situation may predispose to
nderreporting of penetrance of PKP2 mutations in
RVD/C families. Second, all probands were recruited
hrough our research registry. This method of ascertainment
ay have led to an overestimate of penetrance, as families
ith multiple affected members may have been particularly
ikely to enroll in our registry. Third, self-reports of onset of
ymptoms of ARVD/C are vulnerable to recall bias, as
amily members are asked to recall age of onset of cardiac
ymptoms that were sometimes not documented in the
edical record. Similarly, age of diagnosis (meeting TFC) is
ependent upon the age at which a proband or family
ember first sought evaluation for ARVD/C. In the case of
amily members, this often followed the diagnosis of an
ffected person in the family. As some family members were
iagnosed as meeting TFC at their first evaluation, the
aplan-Meier curves demonstrating freedom from diagno-
is almost certainly lag the true age meeting diagnostic
riteria. Finally, this study describes penetrance in only 9
amilies. Although it adds significantly to data from the
ther families described previously, there remain limited
ongitudinal data on the course of the disease in family
embers.
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